| Company Name: |
NCE Biomedical Co.,Ltd. |
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
doxorubicin(6-maleimidocaproyl)hydrazone manufacturers
- MC-DOXHZN
-
- $1520.00
-
2026-04-21
- CAS:151038-96-9
- Purity:
- Supply Ability: 10g
- MC-DOXHZN
-
- $1520.00
-
2025-08-22
- CAS:151038-96-9
- Purity:
- Supply Ability: 10g
- DOXO-EMCH
-
- $1.00
-
2020-01-13
- CAS:151038-96-9
- Min. Order: 1g
- Purity: 95-99%
- Supply Ability: 1ton
|
| | doxorubicin(6-maleimidocaproyl)hydrazone Basic information |
| Product Name: | doxorubicin(6-maleimidocaproyl)hydrazone | | Synonyms: | doxorubicin(6-maleimidocaproyl)hydrazone;(E)-N'-(1-((2R,4R)-4-((2S,4R,5R,6R)-4-aMino-5-hydroxy-6-Methyltetrahydro-2H-pyran-2-yloxy)-2,5,12-trihydroxy-7-Methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide;INNO-206 (Aldoxorubicin);DOXO-EMCH;Doxorubicin-EMCH;N'-[(1E)-1-{4-[(3-Amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexane hydrazide;MC-DOXHZN;DOXO-EMCH; DOXORUBICIN-EMCH; INNO206;INNO 206;ALDOXORUBICIN | | CAS: | 151038-96-9 | | MF: | C37H42N4O13 | | MW: | 750.75 | | EINECS: | 200-258-5 | | Product Categories: | | | Mol File: | 151038-96-9.mol |  |
| | doxorubicin(6-maleimidocaproyl)hydrazone Chemical Properties |
| density | 1.60 | | solubility | Soluble in DMSO | | pka | 7.38±0.60(Predicted) |
| | doxorubicin(6-maleimidocaproyl)hydrazone Usage And Synthesis |
| Uses | Doxorubicin-hydrazone-caproyl-maleimide is an albumin-binding prodrug of doxorubicin and a promising clinical candidate for the treatment of a broad range of solid tumors | | Biological Activity | the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (inno-206), formerly known as doxo-emch, is a prodrug of the anticancer agent doxorubicin which selectively binds to the cys34 of circulating albumin and accumulates in solid tumors due to passive targeting[1]. inno-206 shows significantly superior antitumor efficacy over free doxorubicin in a spectrum of preclinical tumor models [2]. | | in vivo | in a murine renal cell carcinoma model and in breast carcinoma xenograft models, inno-206 has shown superior activity over doxorubicin. inno-206 has shown more potent antitumor efficacy than free doxorubicin in the tumor models and is thus a promising clinical candidate for treating a broad range of solid tumors [2]. | | IC 50 | Topoisomerase II; Daunorubicins/Doxorubicins | | references | [1]. kratz f. doxo-emch (inno-206): the first albumin-binding prodrug of doxorubicin to enter |
| | doxorubicin(6-maleimidocaproyl)hydrazone Preparation Products And Raw materials |
|